Concepedia

Gemma L. Kelly

GL

Statistics

Publications

44

Citations

4.4K

H-Index

31

Active since

2001

Affiliations

Walter and Eliza Hall Institute of Medical Research(Current)

The University of Melbourne

University of Birmingham

Cancer Research UK

The Royal Melbourne Hospital

Gemma L. Kelly is an author at Walter and Eliza Hall Institute of Medical Research specializing in life sciences, oncology, and molecular oncology.

ORCID

Publications per year

2001–2024

44

Publications

44

The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models

András Kotschy, Zoltán Szlávik, James B. Murray et al. · Nature · 2016 · 1.1K citations

, , +11

An Inducible Lentiviral Guide RNA Platform Enables the Identification of Tumor-Essential Genes and Tumor-Promoting Mutations In Vivo

Brandon J. Aubrey, Gemma L. Kelly, Andrew J. Kueh et al. · Cell Reports · 2015 · 423 citations · Full text

, , +15

Inhibitors of histone acetyltransferases KAT6A/B induce senescence and arrest tumour growth

Jonathan B. Baell, David J. Leaver, S.J. Hermans et al. · Nature · 2018 · 314 citations · Full text

, , +14

Epstein–Barr virus–associated Burkitt lymphomagenesis selects for downregulation of the nuclear antigen EBNA2

Gemma L. Kelly, Andrew Bell, Alan B. Rickinson · Nature Medicine · 2002 · 224 citations

, , +14

VDAC2 enables BAX to mediate apoptosis and limit tumor development

Hui San Chin, Xiang Li, Iris K. L. Tan et al. · Nature Communications · 2018 · 192 citations · Full text

, , +17

1–5 of 44